antiangiogenic


Also found in: Dictionary, Wikipedia.
Related to antiangiogenic: Antiangiogenic Therapy

antiangiogenic

(ăn′tē-ăn′jē-ō-jĕn′ĭk, ăn′tī-)
adj.
Of or relating to a naturally occurring substance, drug, or other compound that can destroy or interfere with the fine network of blood vessels needed by tumors to grow and metastasize.

antiangiogenic (anˈ·tī·anˈ·jē·ō·jenˑ·ik),

n a drug or substance used to stop the growth of tumors and progression of cancers by limiting the pathologic formation of new blood vessels (angiogenesis).
References in periodicals archive ?
Inhibition of mitochondrial adenosine triphosphate (ATP) with drug candidates such as ME-344 may have significant potential in combination with antiangiogenic agents that are widely used biologic agents in oncology, but acquired resistance to antiangiogenics is a major problem in cancer therapeutics.
Furthermore, the antiangiogenic property was evaluated using ex vivo rat aorta ring assay.
Placental ischemia leads to the upregulation of hypoxia-inducible transcription factors that control expression of sFlt1, a key antiangiogenic factor that is abnormally expressed in PE.
Biomarkers of response and resistance to antiangiogenic therapy.
Blocking angiogenesis is a validated effective therapeutic approach against cancer, and several antiangiogenic agents (Avastin, Sutent, Nexavar, Votrient, Inlyta, Zaltrap, Stivarga, etc.
As a result, they developed a compound called Sphinx, which can switch the production of VEGF from the proangiogenic form to the antiangiogenic form to block the formation of new blood vessels, and cause the tumours to starve themselves, preventing the growth and spread of the cancer.
increase the total VEGF expression level, but differentially influence pro-angiogenic and antiangiogenic isoforms.
10) Aminobisphosphonates (alendronate and pamidronate) also have an antiangiogenic effect, (3,4) which, while preventing metastatic disease to the bone, may play a role in the pathogenesis.
A position paper on Medication Related Osteonecrosis of the Jaw (MRONJ), released by the American Association of Oral and Maxillofacial Surgeons, expands the scope of the condition previously referred to as Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) and changes its name to reflect the antiresorptive (denosumab) and antiangiogenic therapies that have recently been associated with the condition.
5] In another large phase III trial in 410 patients previously pre-treated with one or more antiangiogenic agents, randomized to receive EV or placebo, there was a significant increase in progression-free survival (PFS) in patients treated with EV.
Studies also show that it may have antibacterial, anticollagenase, antioxidative and antiangiogenic activities.